Baricitinib works better than methotrexate for severe alopecia areata.
36 citations
,
July 2022 in “Journal of Medicinal Chemistry” Therapies targeting the androgen receptor are being developed to treat prostate cancer and improve bone and muscle health.
31 citations
,
January 2017 in “Advances in Experimental Medicine and Biology” Low testosterone and 5α-reductase inhibitors can harm men's metabolic and sexual health; testosterone therapy may help, but discussing 5α-RIs' side effects is important.
4 citations
,
May 2018 in “Electronic Journal of Biotechnology” All-trans retinoic acid at high doses harms goat hair growth cells and could be bad for hair growth.
1 citations
,
December 1970 in “European journal of endocrinology” Reversed sequential therapy with cyproterone acetate was effective for treating women with hirsutism and related conditions.
April 2024 in “The Journal of urology/The journal of urology” 5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.
April 2024 in “Expert opinion on emerging drugs” New treatments for male hair loss are being explored to improve effectiveness and reduce side effects.
July 2014 in “Urologia Journal” 5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.
9 citations
,
July 2019 in “Dermatologic therapy” Alitretinoin can effectively treat frontal fibrosing alopecia.
May 2023 in “Journal of Drugs in Dermatology” REVIVV® serum improves hair growth and reduces shedding in androgenetic alopecia.
23 citations
,
December 1995 in “Archives of Dermatology” Combination therapy improves hair growth in advanced hair loss.
6 citations
,
May 2008 in “Current Opinion in Oncology” 2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.
5 citations
,
February 2025 in “Pediatric Dermatology” Ritlecitinib was generally well tolerated in children with alopecia areata.
350 citations
,
June 1989 in “The American Journal of Medicine” Itraconazole is potentially effective for treating invasive aspergillosis, but more research is needed.
September 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” AR-27 E-Chol siRNA can effectively promote hair regrowth for androgenetic alopecia.
39 citations
,
January 2010 in “Trends in Parasitology” Anticancer drugs like methotrexate and trimetrexate could be effective and safe for treating malaria at low doses.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
February 2020 in “Definitions” 5 Alpha-Reductase Inhibitors reduce the effects of testosterone by blocking its conversion into a stronger form.
5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
July 2024 in “Journal of Investigative Dermatology” ITK inhibitors may effectively treat alopecia areata.
3 citations
,
August 2017 in “Dermatologic therapy” UVA-1 phototherapy might help treat alopecia areata.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib was effective in treating both early and late onset alopecia areata.
December 2025 in “Frontiers in Medicine” Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.
Ritlecitinib is a new treatment for severe hair loss in people 12 and older.
92 citations
,
June 2005 in “Journal of Investigative Dermatology” All-trans retinoic acid causes hair loss by increasing TGF-β2 in hair follicle cells.
January 2021 in “Springer eBooks” Combining PRP with other treatments can improve hair loss outcomes.
July 2024 in “Reactions Weekly” May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.